Arcturus Therapeutics Holdings, Inc. (ARCT)

Arcturus Therapeutics' stock price has experienced significant volatility in the past six months, declining by 12.82% between April 28, 2025, and October 28, 2025. A major event impacting the stock occurred on October 22-23, 2025, when the stock plunged following the announcement of underwhelming interim Phase 2 data for its cystic fibrosis treatment, ARCT-032, leading to analyst downgrades. Prior to this, on August 11, 2025, Arcturus announced its Q2 2025 financial results, reporting an EPS of -$0.34 and quarterly revenue of $28.30 million, both exceeding expectations.

For Arcturus Therapeutics' vaccine products, particularly those targeting respiratory illnesses like COVID-19 and influenza, there is an expectation of demand seasonality, with demand for COVID-19 vaccines anticipated to be concentrated in the second half of the year. For its rare disease therapeutics, demand is generally driven by the prevalence of these chronic conditions and the ongoing need for treatment, rather than distinct seasonal fluctuations.

Arcturus Therapeutics Holdings, Inc. is an American RNA medicines biotechnology company focused on the discovery, development, and commercialization of therapeutics for rare diseases and infectious diseases, operating within the Health Technology sector, specifically in the Pharmaceutical industry. The company specializes in messenger RNA (mRNA) medicines and vaccines, leveraging its proprietary LUNAR® lipid-mediated delivery and STARR® mRNA technologies. Its major products and pipeline candidates include KOSTAIVE®, the first self-amplifying mRNA (sa-mRNA) COVID-19 vaccine to be approved globally, ARCT-810 (LUNAR-OTC), an mRNA-based therapeutic candidate in Phase 2 clinical trials for treating ornithine transcarbamylase deficiency (OTCD), ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate in Phase 2 clinical trials for cystic fibrosis (CF), LUNAR-FLU (ARCT-2138), a seasonal influenza vaccine candidate in Phase 1 clinical trials, LUNAR-H5N1 (ARCT-2304), a pandemic influenza vaccine candidate in Phase 1 clinical trials, and ARCT-2301 and ARCT-2303, COVID-19 vaccine candidates in Phase 3 clinical trials.

Arcturus Therapeutics is headquartered in San Diego, California, USA, and has a global presence through collaborations and intellectual property. It maintains an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus and has a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Its extensive patent portfolio spans the U.S., Europe, Japan, China, and other countries. The company's COVID-19 vaccine, KOSTAIVE®, has received authorization in Japan (2023) and the European Union (February 2025).

Arcturus Therapeutics' brand reputation in the past year has been significantly impacted by its clinical trial results, particularly the underwhelming interim Phase 2 data for its cystic fibrosis treatment (ARCT-032), which led to a substantial drop in stock price and analyst downgrades. Positive developments include the authorization of its self-amplifying mRNA COVID-19 vaccine, KOSTAIVE®, in Japan in 2023 and the European Union in February 2025, demonstrating the company's capability in bringing mRNA vaccines to market.

Arcturus Therapeutics Holdings, Inc. is primarily owned by institutional shareholders, who hold approximately 94.89% of the company's stock, with insiders owning about 13.58%. Major institutional owners include Federated Hermes, Inc., BlackRock, Inc., Sumitomo Mitsui Trust Holdings, Inc., Nikko Asset Management Americas, Inc., Vanguard Group Inc, ARK Investment Management LLC and State Street Corp. Joseph E. Payne, the company's President, CEO, and Director, is the largest individual shareholder, owning 1.48 million shares, representing 5.45% of the company.